A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Key facts
- Where
- Milwaukee, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Froedtert & the Medical College of WisconsinMilwaukee, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT07572929
- Record updated
- 13 October 2026
- Original description
This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.Read full original descriptionShow less
This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and/or molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.
Inclusion: Age ≥18 years at time of transplant; Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia; Pre-transplant disease assessment must include at least one:; Immunophenotypic assessment by flow for aberrant blasts; NGS to identify persistence of malignant clones using a standard clinically available assay; PCR based measurement of prior identified mutations (if applicable); Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion: None.